Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia

  • Kotaro Arita
  • Takeshi Kondo
  • Junichi Sugita
  • Akio Shigematsu
  • Souichi Shiratori
  • Kentaro Wakasa
  • Atsushi Yasumoto
  • Makoto Ibata
  • Yusuke Shono
  • Misato Kikuchi
  • Hideki Goto
  • Yukari Takeda
  • Mutsumi Takahata
  • Naoko Kato
  • Mitsufumi Nishio
  • Shuichi Ota
  • Junji Tanaka
  • Masahiro Imamura
Case Report

Abstract

The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m2 for 3 days, VCR 1.4 mg/m2 for 1 day, and PSL 60 mg/m2 for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1,055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL.

Keywords

Acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation Non-CR Refractory leukemia Induction failure 

References

  1. 1.
    Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2008;14:568–75.PubMedCrossRefGoogle Scholar
  2. 2.
    Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant. 2008;42:791–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006;37:45–50.PubMedGoogle Scholar
  6. 6.
    Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol. 2005;80:181–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Doney K, Hägglund H, Leisenring W, Chauncey T, Appelbaum FR, Storb R. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2003;9:472–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Inoue M, Yasui M, Sawada A, Koyama M, Kondo O, Miyamura T, et al. Encouraging results of stem cell transplantation following a melphalan-preceding intensified preparative regimen for refractory acute leukemia in children. Rinsho Ketsueki. 2007;48:1470–7. (in Japanese).PubMedGoogle Scholar
  10. 10.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant. 2009;15:1376–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Mathé G, Hayat M, Schwarzenberg L, Amiel JL, Schneider M, Cattan A, et al. Acute lymphoblastic leukemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms. Lancet. 1967;290:380–2.CrossRefGoogle Scholar
  12. 12.
    Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025–37.PubMedGoogle Scholar
  13. 13.
    Durrant IJ, Prentice HG, Richards SM. Intensification of treatment for adults with acute lymphoblastic leukemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. Br J Haematol. 1997;99:84–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, et al. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer. doi:10.1007/s00520-011-1116-x (published online February 15, 2011).
  16. 16.
    Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396–403.PubMedCrossRefGoogle Scholar
  17. 17.
    Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010;151:430–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol. 2008;26:3756–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. doi:10.1111/j.1365-2141.2011.08762.x (published online July 7, 2011).
  21. 21.
    McGregor BA, Brown AW, Osswald MB, Savona MR. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol. 2009;84:228–30.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Kotaro Arita
    • 1
    • 2
  • Takeshi Kondo
    • 1
  • Junichi Sugita
    • 1
  • Akio Shigematsu
    • 1
  • Souichi Shiratori
    • 1
  • Kentaro Wakasa
    • 1
  • Atsushi Yasumoto
    • 1
  • Makoto Ibata
    • 1
  • Yusuke Shono
    • 1
  • Misato Kikuchi
    • 1
  • Hideki Goto
    • 1
  • Yukari Takeda
    • 1
  • Mutsumi Takahata
    • 1
  • Naoko Kato
    • 1
  • Mitsufumi Nishio
    • 1
  • Shuichi Ota
    • 1
  • Junji Tanaka
    • 1
  • Masahiro Imamura
    • 1
  1. 1.Stem Cell Transplantation CenterHokkaido University HospitalSapporoJapan
  2. 2.Third Department of Internal Medicine, Graduate School of MedicineUniversity of ToyamaToyamaJapan

Personalised recommendations